Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma
NCT ID: NCT02725242
Last Updated: 2017-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
77 participants
INTERVENTIONAL
2016-03-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period
NCT04215848
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
NCT05202262
Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma
NCT01676987
Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics
NCT02574975
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
NCT02105012
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Once-daily budesonide/formoterol (160/4.5 μg/d)
once-daily budesonide/formoterol (160/4.5 μg/d)
Budesonide/formoterol (160/4.5 μg/d)
After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
Twice-daily Budesonide (200μg)
twice-daily Budesonide (400μg/d)
Budesonide (400μg/d)
After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Budesonide/formoterol (160/4.5 μg/d)
After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
Budesonide (400μg/d)
After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age more than 18 year-old
* Patients who able to do spirometry without contraindication
* History smoking less than 10 pack-years
Exclusion Criteria
* History of pulmonary tuberculosis with residual lung lesion by chest radiograph
* recent serious medical condition such as myocardial infarction, stroke, pneumonia etc.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hat Yai Medical Education Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Narongwit Nakwan
Head of Pulmonology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Narongwit Nakwan, M.D.
Role: STUDY_CHAIR
HatYai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Narongwit Nakwan
Hat Yai, Changwat Songkhla, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
064/2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.